Highly Potent Fully Human anti-VISTA Antibodies A New Target Checkpoint Inhibitor against Immunosuppressive Myeloid Cells
Thierry Guillaudeux, PhD, Chief Scientific Officer Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting | November 12, 2020
Kineta Presents New Preclinical Data at the 2020 SITC Annual Meeting on its VISTA Antagonist Antibodies
Kineta Presents New Preclinical Data at the 2020 SITC Annual Meeting on its VISTA Antagonist Antibodies Preclinical data demonstrates that VISTA is a novel target checkpoint against immunosuppressive ...